Linked Life Data

15687816

Source:http://linkedlifedata.com/resource/pubmed/id/15687816

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15687816rdf:typepubmed:Citationlld:pubmed
pubmed-article:15687816lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:15687816lifeskim:mentionsumls-concept:C0038435lld:lifeskim
pubmed-article:15687816lifeskim:mentionsumls-concept:C0018787lld:lifeskim
pubmed-article:15687816lifeskim:mentionsumls-concept:C0034843lld:lifeskim
pubmed-article:15687816lifeskim:mentionsumls-concept:C0005910lld:lifeskim
pubmed-article:15687816lifeskim:mentionsumls-concept:C0043094lld:lifeskim
pubmed-article:15687816lifeskim:mentionsumls-concept:C0151956lld:lifeskim
pubmed-article:15687816lifeskim:mentionsumls-concept:C0475224lld:lifeskim
pubmed-article:15687816lifeskim:mentionsumls-concept:C0766326lld:lifeskim
pubmed-article:15687816lifeskim:mentionsumls-concept:C1879647lld:lifeskim
pubmed-article:15687816lifeskim:mentionsumls-concept:C1314939lld:lifeskim
pubmed-article:15687816lifeskim:mentionsumls-concept:C1292733lld:lifeskim
pubmed-article:15687816pubmed:issue1lld:pubmed
pubmed-article:15687816pubmed:dateCreated2005-2-2lld:pubmed
pubmed-article:15687816pubmed:abstractTextHypothyroid heart displays a phenotype of cardioprotection against ischemia and this study investigated whether administration of dronedarone, an amiodarone-like compound that has been shown to preferentially antagonize thyroid hormone binding to thyroid hormone receptor alpha1 (TRalpha1), results in a similar effect. Dronedarone was given in Wistar rats (90 mg/kg, once daily (od) for 2 weeks) (DRON), while untreated animals served as controls (CONT). Hypothyroidism (HYPO) was induced by propylthiouracil administration. Isolated rat hearts were perfused in Langendorff mode and subjected to 20 minutes of zero-flow global ischemia (I) followed by 45 minutes of reperfusion (R). 3,5,3' Triiodothyronine remained unchanged while body weight and food intake were reduced. alpha-Myosin heavy chain (alpha-MHC) decreased in DRON while beta-myosin heavy chain (beta-MHC) and sarcoplasmic reticulum Ca2+ adenosine triphosphatase (ATPase) expression (SERCA) was similar to CONT. In HYPO, alpha-MHC and SERCA were decreased while beta-MHC was increased. Myocardial glycogen content was increased in both DRON and HYPO. In DRON, resting heart rate and contractility were reduced and ischemic contracture was significantly suppressed while postischemic left ventricular end-diastolic pressure and lactate dehydrogenase release (IU/L min) after I/R were significantly decreased. In conclusion, dronedarone treatment results in cardioprotection by selectively mimicking hypothyroidism. This is accompanied by a reduction in body weight because of the suppression of food intake. TRs might prove novel pharmacologic targets for the treatment of cardiovascular illnesses.lld:pubmed
pubmed-article:15687816pubmed:languageenglld:pubmed
pubmed-article:15687816pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15687816pubmed:citationSubsetIMlld:pubmed
pubmed-article:15687816pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15687816pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15687816pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15687816pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15687816pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15687816pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15687816pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15687816pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15687816pubmed:statusMEDLINElld:pubmed
pubmed-article:15687816pubmed:monthJanlld:pubmed
pubmed-article:15687816pubmed:issn1050-7256lld:pubmed
pubmed-article:15687816pubmed:authorpubmed-author:CokkinosDenni...lld:pubmed
pubmed-article:15687816pubmed:authorpubmed-author:VaronosDennis...lld:pubmed
pubmed-article:15687816pubmed:authorpubmed-author:PaizisIoannis...lld:pubmed
pubmed-article:15687816pubmed:authorpubmed-author:PantosConstan...lld:pubmed
pubmed-article:15687816pubmed:authorpubmed-author:MourouzisIord...lld:pubmed
pubmed-article:15687816pubmed:authorpubmed-author:MalliopoulouV...lld:pubmed
pubmed-article:15687816pubmed:authorpubmed-author:TzeisStyliano...lld:pubmed
pubmed-article:15687816pubmed:authorpubmed-author:MoraitisPanag...lld:pubmed
pubmed-article:15687816pubmed:authorpubmed-author:SfakianoudisK...lld:pubmed
pubmed-article:15687816pubmed:issnTypePrintlld:pubmed
pubmed-article:15687816pubmed:volume15lld:pubmed
pubmed-article:15687816pubmed:ownerNLMlld:pubmed
pubmed-article:15687816pubmed:authorsCompleteYlld:pubmed
pubmed-article:15687816pubmed:pagination16-23lld:pubmed
pubmed-article:15687816pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:meshHeadingpubmed-meshheading:15687816...lld:pubmed
pubmed-article:15687816pubmed:year2005lld:pubmed
pubmed-article:15687816pubmed:articleTitleDronedarone administration prevents body weight gain and increases tolerance of the heart to ischemic stress: a possible involvement of thyroid hormone receptor alpha1.lld:pubmed
pubmed-article:15687816pubmed:affiliationDepartment of Pharmacology, University of Athens, Athens, Greece. cpantos@cc.uoa.grlld:pubmed
pubmed-article:15687816pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15687816pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15687816lld:pubmed